<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Acta Naturae</journal-id><journal-title-group><journal-title xml:lang="en">Acta Naturae</journal-title><trans-title-group xml:lang="ru"><trans-title>Acta Naturae</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-8251</issn><publisher><publisher-name xml:lang="en">Acta Naturae Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">27696</article-id><article-id pub-id-type="doi">10.32607/actanaturae.27696</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Research Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Novel nicotinic acetylcholine receptor inhibitors derived from oleoylcholine analogs</article-title><trans-title-group xml:lang="ru"><trans-title>Новые ингибиторы никотиновых ацетилхолиновых рецепторов на основе аналогов олеоилхолина</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vladykina</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Владыкина</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kokaeva</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Кокаева</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kasheverov</surname><given-names>I. E.</given-names></name><name xml:lang="ru"><surname>Кашеверов</surname><given-names>И. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gretskaya</surname><given-names>N. M.</given-names></name><name xml:lang="ru"><surname>Грецкая</surname><given-names>Н. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zinchenko</surname><given-names>G. N.</given-names></name><name xml:lang="ru"><surname>Зинченко</surname><given-names>Г. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tsetlin</surname><given-names>V. I.</given-names></name><name xml:lang="ru"><surname>Цетлин</surname><given-names>В. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Utkin</surname><given-names>Yu. N.</given-names></name><name xml:lang="ru"><surname>Уткин</surname><given-names>Ю. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bezuglov</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Безуглов</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shelukhina</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Шелухина</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Department of Molecular Neuroimmune Signaling</p></bio><bio xml:lang="ru"><p>отдел молекулярной нейроиммунной сигнализации</p></bio><email>shelukhina.iv@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Государственный научный центр Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-22" publication-format="electronic"><day>22</day><month>04</month><year>2026</year></pub-date><volume>18</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>36</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2025-05-06"><day>06</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-08-06"><day>06</day><month>08</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Vladykina M.V., Kokaeva I.S., Kasheverov I.E., Gretskaya N.M., Zinchenko G.N., Tsetlin V.I., Utkin Y.N., Bezuglov V.V., Shelukhina I.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Владыкина М.В., Кокаева И.С., Кашеверов И.Е., Грецкая Н.М., Зинченко Г.Н., Цетлин В.И., Уткин Ю.Н., Безуглов В.В., Шелухина И.В.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Vladykina M.V., Kokaeva I.S., Kasheverov I.E., Gretskaya N.M., Zinchenko G.N., Tsetlin V.I., Utkin Y.N., Bezuglov V.V., Shelukhina I.V.</copyright-holder><copyright-holder xml:lang="ru">Владыкина М.В., Кокаева И.С., Кашеверов И.Е., Грецкая Н.М., Зинченко Г.Н., Цетлин В.И., Уткин Ю.Н., Безуглов В.В., Шелухина И.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://actanaturae.ru/2075-8251/article/view/27696">https://actanaturae.ru/2075-8251/article/view/27696</self-uri><abstract xml:lang="en"><p>Fatty acid-acylated cholines, a recently identified class of endogenous compounds, have been detected in both human and animal organisms. Our prior work established that oleoylcholine (Ol-Chol), and other acylcholines, at micromolar levels, modulate the cholinergic system and are suitable as cationic lipids for introducing nucleic acids into human and animal cells. The present research examines the interaction with the nicotinic acetylcholine receptors (nAChR) of two ionic forms of Ol-Chol and two synthesized cationic lipids, each featuring a quaternary ammonium moiety and two oleic acid chains. A radioligand binding assay revealed that the affinity of acylcholines and synthetic cationic lipids for the muscle-type nAChR surpasses that for the human neuronal α7 nAChR by a factor of 2–5.5. Oleoylcholine iodide demonstrated a two-fold higher efficacy of mesylate in binding to the orthosteric site of muscle and α7 nAChR. In a functional calcium imaging assay, both compounds exhibited superior inhibition of α7 nAChR by several orders of magnitude, suggesting potential interaction with allosteric binding sites. Compared to oleoylcholine, synthetic cationic lipids demonstrated markedly reduced efficacy in binding to α7 nAChRs and, in contrast to oleoylcholine, induced a substantial cytotoxic impact on SH-SY5Y neuroblastoma cells, a phenomenon unaffected by specific nAChR ligands. As a result, the nAChR-inhibitory properties are attributed to the quaternary ammonium group present in all studied compounds. However, the modification of the lipophilic moiety with two oleic acid residues curbs these properties but enhances cytotoxic activity through an alternative mechanism independent of nAChR.</p></abstract><trans-abstract xml:lang="ru"><p>Ацилированные жирными кислотами холины – недавно открытый класс эндогенных соединений человека и животных. Ранее мы показали, что олеоилхолин (Ol-Chol) и другие ацилхолины в микромолярном диапазоне концентраций являются модуляторами холинергической системы и могут использоваться в качестве катионных липидов для доставки нуклеиновых кислот в клетки человека и животных. В настоящей работе исследовано взаимодействие с никотиновыми ацетилхолиновыми рецепторами (нАХР) двух ионных форм Ol-Chol и двух синтетических катионных липидов, содержащих четвертичную аммониевую группу и два остатка олеиновой кислоты. Радиолигандным анализом показано, что сродство обоих ацилхолинов и синтетических катионных липидов к мышечному типу нАХР в 2–5.5 раза выше, чем к нейрональному α7 нАХР человека. Иодид олеоилхолина в 2 раза более эффективно, чем мезилат, взаимодействовал с ортостерическим сайтом связывания мышечного и α7 нАХР, а в функциональном тесте кальциевого имиджинга оба соединения оказались на порядок более эффективными ингибиторами α7 нАХР, что может свидетельствовать об их дополнительном действии через аллостерические участки связывания рецептора. Синтетические катионные липиды заметно уступали олеоилхолину в сродстве к α7 нАХР и, в отличие от него, оказывали выраженное цитотоксическое действие на клетки нейробластомы SH-SY5Y, которое не блокировали специфические лиганды нАХР. Таким образом, четвертичная аммониевая группа в составе всех исследованных соединений придает им свойства ингибиторов нАХР, а усложнение структуры липофильной части молекулы введением двух остатков олеиновой кислоты ухудшает эти свойства, но усиливает их цитотоксическое действие по независимому от нАХР механизму.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acylated cholines</kwd><kwd>nicotinic acetylcholine receptor</kwd><kwd>inhibitor</kwd><kwd>DOTAP</kwd><kwd>SH-SY5Y</kwd><kwd>cytotoxicity</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ацилированные холины</kwd><kwd>никотиновый ацетилхолиновый рецептор</kwd><kwd>ингибитор</kwd><kwd>DOTAP</kwd><kwd>SH-SY5Y</kwd><kwd>цитотоксичность</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="en">Ministry of Science and Higher Education of the Russian Federation</institution></institution-wrap><institution-wrap><institution xml:lang="ru">Министерство науки и высшего образования Российской Федерации</institution></institution-wrap></funding-source><award-id>075-15-2024-536</award-id></award-group><funding-statement xml:lang="en">This work was supported by a grant from the Ministry of Science and Higher Education of the Russian Federation (project No. 075-15-2024-536).</funding-statement><funding-statement xml:lang="ru">Работа поддержана грантом Министерства науки и высшего образования РФ (номер соглашения 075-15-2024-536).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Zarei I, Oppel RC, Borresen EC, Brown RJ, Ryan EP. Modulation of plasma and urine metabolome in colorectal cancer survivors consuming rice bran. Integr Food Nutr Metab. 2019;6(3):10. doi: 10.15761/IFNM.1000252</mixed-citation><mixed-citation xml:lang="ru">Zarei I, Oppel RC, Borresen EC, et al. Modulation of plasma and urine metabolome in colorectal cancer survivors consuming rice bran. Integr Food Nutr Metab. 2019;6(3):10. doi: 10.15761/IFNM.1000252</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Vorkas PA, Isaac G, Anwar MA, et al. Untargeted UPLC-MS profiling pipeline to expand tissue metabolome coverage: application to cardiovascular disease. Anal Chem. 2015;87(8):4184-4193. doi: 10.1021/ac503775m</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Vorkas PA, Shalhoub J, Isaac G, et al. Metabolic phenotyping of atherosclerotic plaques reveals latent associations between free cholesterol and ceramide metabolism in atherogenesis. J Proteome Res. 2015;14(3):1389-1399. doi: 10.1021/pr5009898</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Zeleznik OA, Poole EM, Lindstrom S, et al. Metabolomic analysis of 92 pulmonary embolism patients from a nested case-control study identifies metabolites associated with adverse clinical outcomes. J Thromb Haemost. 2018;16(3):500-507. doi: 10.1111/jth.13937</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Akimov MG, Kudryavtsev DS, Kryukova EV, et al. Arachidonoylcholine and Other Unsaturated Long-Chain Acylcholines Are Endogenous Modulators of the Acetylcholine Signaling System. Biomolecules. 2020;10(2):283. doi: 10.3390/biom10020283</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Arunrungvichian K, Vajragupta O, Hayakawa Y, Pongrakhananon V. Targeting Alpha7 Nicotinic Acetylcholine Receptors in Lung Cancer: Insights, Challenges, and Therapeutic Strategies. ACS Pharmacol Transl Sci. 2024;7(1):28-41. doi: 10.1021/acsptsci.3c00138</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gretskaya N, Akimov M, Andreev D, et al. Multicomponent Lipid Nanoparticles for RNA Transfection. Pharmaceutics. 2023;15(4):1289. doi: 10.3390/pharmaceutics15041289</mixed-citation></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Ponti F, Campolungo M, Melchiori C, Bono N, Candiani G. Cationic lipids for gene delivery: many players, one goal. Chem Phys Lipids. 2021;235:105032. doi: 10.1016/j.chemphyslip.2020.105032</mixed-citation><mixed-citation xml:lang="ru">Ponti F, Campolungo M, Melchiori C, et al. Cationic lipids for gene delivery: many players, one goal. Chem Phys Lipids. 2021;235:105032. doi: 10.1016/j.chemphyslip.2020.105032</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst. 2004;21(4):257-317. doi: 10.1615/critrevtherdrugcarriersyst.v21.i4.10</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Cecchini M, Corringer PJ, Changeux JP. The Nicotinic Acetylcholine Receptor and Its Pentameric Homologs: Toward an Allosteric Mechanism of Signal Transduction at the Atomic Level. Annu Rev Biochem. 2024;93(1):339-366. doi: 10.1146/annurev-biochem-030122-033116</mixed-citation><mixed-citation xml:lang="ru">Cecchini M, Corringer PJ, Changeux JP. The Nicotinic Acetylcholine Receptor and Its Pentameric Homologs: Toward an Allosteric Mechanism of Signal Transduction at the Atomic Level. Annual Review of Biochemistry. 2024;93(1):339-366. doi: 10.1146/annurev-biochem-030122-033116</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><mixed-citation>Zoli M, Pucci S, Vilella A, Gotti C. Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors. Curr Neuropharmacol. 2018;16(4):338-349. doi: 10.2174/1570159X15666170912110450</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Shelukhina I, Siniavin A, Kasheverov I, Ojomoko L, Tsetlin V, Utkin Y. alpha7- and alpha9-Containing Nicotinic Acetylcholine Receptors in the Functioning of Immune System and in Pain. Int J Mol Sci. 2023;24(7):6524. doi: 10.3390/ijms24076524</mixed-citation><mixed-citation xml:lang="ru">Shelukhina I, Siniavin A, Kasheverov I, et al. alpha7- and alpha9-Containing Nicotinic Acetylcholine Receptors in the Functioning of Immune System and in Pain. Int J Mol Sci. 2023;24(7):6524. doi: 10.3390/ijms24076524</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Soares AR, Picciotto MR. Nicotinic regulation of microglia: potential contributions to addiction. J Neural Transm (Vienna). 2024;131(5):425-435. doi: 10.1007/s00702-023-02703-9</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Roa-Vidal N, Rodríguez-Aponte AS, Lasalde-Dominicci JA, Capó-Vélez CM, Delgado-Vélez M. Cholinergic Polarization of Human Macrophages. Int J Mol Sci. 2023;24(21):15732. doi: 10.3390/ijms242115732</mixed-citation><mixed-citation xml:lang="ru">Roa-Vidal N, Rodriguez-Aponte AS, Lasalde-Dominicci JA, et al. Cholinergic Polarization of Human Macrophages. Int J Mol Sci. 2023;24(21):15732. doi: 10.3390/ijms242115732</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Ma KG, Qian YH. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer’s disease. Neuropeptides. 2019;73:96-106. doi: 10.1016/j.npep.2018.12.003</mixed-citation></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Kudryavtsev D, Shelukhina I, Vulfius C, et al. Natural compounds interacting with nicotinic acetylcholine receptors: from low-molecular weight ones to peptides and proteins. Toxins (Basel). 2015;7(5):1683-1701. doi: 10.3390/toxins7051683</mixed-citation><mixed-citation xml:lang="ru">Kudryavtsev D, Shelukhina I, Vulfius C, et al. Natural compounds interacting with nicotinic acetylcholine receptors: from low-molecular weight ones to peptides and proteins. Toxins. 2015;7(5):1683-1701. doi: 10.3390/toxins7051683</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Ivanov IA, Siniavin AE, Palikov VA, et al. Analogs of 6-Bromohypaphorine with Increased Agonist Potency for alpha7 Nicotinic Receptor as Anti-Inflammatory Analgesic Agents. Mar Drugs. 2023;21(6):368. doi: 10.3390/md21060368</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Severyukhina MS, Ojomoko LO, Shelukhina IV, et al. Non-conventional toxin WTX and its disulfide-fixed synthetic fragments: Interaction with nicotinic acetylcholine receptors and reduction of blood pressure. Int J Biol Macromol. 2025;288:138626. doi: 10.1016/j.ijbiomac.2024.138626</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Bezuglov VV, Zinchenko GN, Nikitina LA, Buznikov GA. [Arachidonoylcholine and N,N-dimethylaminoethyl arachidonate are new cholinergic compounds]. Bioorg Khim. 2001;27(3):227-230. doi: 10.1023/a:1011341623358</mixed-citation><mixed-citation xml:lang="ru">Безуглов ВВ, Зинченко ГН, Никитина ЛА, Бузников ГА. Арахидоноилхолин и N,N-диметиламиноэтиларахидонат – новые холинэргические вещества. Биоорг. химия. 2001;27(3):227-230. doi: 10.1023/a:1011341623358</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Massing U, Kley JT, Gurtesch L, Fankhaenel S. A simple approach to DOTAP and its analogs bearing different fatty acids. Chem Phys Lipids. 2000;105(2):189-191. doi: 10.1016/s0009-3084(00)00121-3</mixed-citation><mixed-citation xml:lang="ru">Massing U, Kley JT, Gurtesch L, Fankhaenel S. A simple approach to DOTAP and its analogs bearing different fatty acids. Chemistry and Physics of Lipids. 2000;105(2):189-191. doi: 10.1016/s0009-3084(00)00121-3</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J. Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol Pharmacol. 1997;51(5):776-784. doi: 10.1124/mol.51.5.776</mixed-citation><mixed-citation xml:lang="ru">Peng X, Gerzanich V, Anand R, et al. Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol Pharmacol. 1997;51(5):776-784. doi: 10.1124/mol.51.5.776</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Mucchietto V, Fasoli F, Pucci S, et al. α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. Br J Pharmacol. 2018;175(11):1957-1972. doi: 10.1111/bph.13954</mixed-citation><mixed-citation xml:lang="ru">Mucchietto V, Fasoli F, Pucci S, et al. alpha9- and alpha7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line. Br J Pharmacol. 2018;175(11):1957-1972. doi: 10.1111/bph.13954</mixed-citation></citation-alternatives></ref></ref-list></back></article>
